FY2025 Earnings Estimate for Harrow Issued By William Blair

Harrow, Inc. (NASDAQ:HROW) – Equities researchers at William Blair raised their FY2025 earnings per share estimates for Harrow in a note issued to investors on Monday, September 29th. William Blair analyst L. Hanbury-Brown now anticipates that the company will earn $0.37 per share for the year, up from their previous forecast of $0.33. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Harrow’s current full-year earnings is ($0.53) per share. William Blair also issued estimates for Harrow’s Q4 2025 earnings at $0.40 EPS, Q2 2026 earnings at $0.47 EPS, Q3 2026 earnings at $0.44 EPS, Q4 2026 earnings at $0.80 EPS and FY2026 earnings at $1.52 EPS.

HROW has been the topic of several other reports. B. Riley increased their target price on Harrow from $65.00 to $70.00 and gave the stock a “buy” rating in a research report on Tuesday, September 23rd. Lake Street Capital increased their target price on Harrow from $42.00 to $70.00 and gave the stock a “buy” rating in a research report on Monday. Zacks Research downgraded Harrow from a “strong-buy” rating to a “hold” rating in a research report on Friday, September 12th. BTIG Research reiterated a “buy” rating and set a $63.00 target price on shares of Harrow in a research report on Wednesday, September 24th. Finally, Craig Hallum increased their target price on Harrow from $54.00 to $64.00 and gave the stock a “buy” rating in a research report on Tuesday, September 23rd. Seven investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $67.83.

Harrow Stock Performance

NASDAQ HROW opened at $48.18 on Tuesday. The business’s 50-day moving average price is $38.94 and its 200 day moving average price is $31.79. Harrow has a twelve month low of $20.85 and a twelve month high of $59.23. The company has a market capitalization of $1.78 billion, a PE ratio of -192.72 and a beta of 0.33. The company has a current ratio of 0.62, a quick ratio of 0.58 and a debt-to-equity ratio of 0.78.

Harrow (NASDAQ:HROW) last released its earnings results on Monday, August 11th. The company reported $0.24 earnings per share for the quarter, topping the consensus estimate of $0.01 by $0.23. Harrow had a negative return on equity of 2.18% and a negative net margin of 4.49%.The firm had revenue of $63.74 million for the quarter, compared to the consensus estimate of $64.23 million. Harrow has set its FY 2025 guidance at EPS.

Institutional Investors Weigh In On Harrow

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Quarry LP acquired a new stake in Harrow during the first quarter worth about $32,000. Raymond James Financial Inc. acquired a new stake in shares of Harrow in the second quarter valued at about $48,000. Tower Research Capital LLC TRC grew its stake in shares of Harrow by 345.0% in the second quarter. Tower Research Capital LLC TRC now owns 3,373 shares of the company’s stock valued at $103,000 after buying an additional 2,615 shares in the last quarter. State of Wyoming acquired a new stake in shares of Harrow in the first quarter valued at about $97,000. Finally, Strs Ohio acquired a new stake in shares of Harrow in the first quarter valued at about $149,000. 72.76% of the stock is currently owned by institutional investors and hedge funds.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.